Cytodyn Inc (CYDY)

[DonDonDonDon]

Decrease hospitalization from 10.7% to 1.7% , a 63% reduction when compare to placebo.

I found the 10.7% number from the CD10. It was SAE data, not about hospitalization at all. My guess is your 1.7% number came from writting 10.7% while omitting the zero.

In terms of toxicity, adverse events (AEs) of any grade were seen in 33 patients (39.3%), while mild events occurred in 17 (20.2%), moderate in 8 (9.5%), and severe in 8 (9.5%). incidence, frequency, and severity of AEs were lower with leronlimab compared with placebo, in which AEs of any grade were observed in 19 patients (33.9%) versus 14 (50.0%), of mild severity in 12 (21.4%) versus 5 (17.9%), moderate in 2 (3.6%) versus 6 (21.4%), and severe in 5 (8.9%) versus 3 (10.7%), respectively. Eight serious AEs occurred in 56 patients (14%) in the leronlimab arm compared with 11 in 28 patients (39%) from the placebo arm.
https://www.targetedonc.com/view/protocol-filed-with-fda-for-phase-2-trial-of-leronlimab-to-treat-long-hauler-symptoms-of-covid-19